Clinical Trial Update: A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome [Phase 2]

View source ↗

Summary

A double-blind Phase 2 trial of Eisai's drug E5555 in Japanese patients with Acute Coronary Syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• E5555

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Acute Coronary Syndrome | Phase 2 | Status: COMPLETED